Arctic Blue Beverages: The World's First Gin-based Oat Liqueur Comes From Finland
Arctic Blue Beverages Oy, the manufacturer of the international award-winning Arctic Blue Gin, is launching the world's first gin-based oat liqueur. The dairy alternatives market is growing very fast in both Europe and the United States, where growth has been in the triple digits for already two years in a row. Oat is expected to become the largest plant-based raw material in its product field – even exceeding almond - surpassing € 1 billion in sales over the next five years.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210329005264/en/
Arctic Blue Beverages Oy, the manufacturer of Arctic Blue Gin is launching the world's first gin-based oat liqueur. Arctic Blue Oat is vegan and gluten-free, made from organic Finnish oats. (Photo: Business Wire)
Oat replaces milk
The global market for traditional cream-based liqueurs is around 18 million bottles per year, or € 1.5 billion, Drinks Retail News reports. Unlike almost all other cream liqueurs, Arctic Blue Oat is a vegan product. "So far, oat has been mainly used in dairy alternatives. We have noted that oat also works as an excellent base for an alcohol product,” says Valtteri Eroma, CEO of Arctic Blue Beverages.
Mr. Tuomas Kukkonen, a board member of Arctic Blue Beverages, has had a significant role in the product development of the new Arctic Blue Oat. Mr. Kukkonen is the former CEO of the pioneering company Kaslink Oy, manufacturing oat products. In 2019, Kaslink Oy was sold to Fazer Group, a Finnish foods giant.
“Arctic Blue Oat will be available in the Finnish market before summer. After that, it will gradually be available in the rest of the world, during year 2021,” says Eroma.
Finnish organic oats
In the manufacture process of the Arctic Blue Oat, the taste from the second main ingredient, artisan gin, has been thoughtfully taken into attention. Artisan gin is made in Ilomantsi, the most eastern community of Finland.
Unlike conventional oat drinks, found in daily retail stores, Arctic Blue Oat contains only water and oats, without additives. It contains only gluten-free, organic, Finnish oats.
Globally, the market for dairy alternatives products has doubled in the last five years, from around € 10 billion to € 20 billion. Compared to dairy products, the key benefits of oats are the lower environmental impact, health benefits and the great taste.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210329005264/en/
Contact information
Jan Erola
Communication and PR
jan.erola@arcticbluebeverages.com
+358 40 5064612
Valtteri Eroma
Chief Executive Officer
valtteri.eroma@arcticbluebeverages.com
+358 40 550 1343
Tuomas Kukkonen
Member of the board
tuomas.kukkonen@arcticbluebeverages.com
+358 40 591 2753
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Making Science Unveils ‘AWAKE’: The AI Venture Studio Industrialising Startup Creation and AI-First Innovative Solutions23.12.2025 20:51:00 CET | Press Release
Making Science, the global digital acceleration consultancy, today announced the launch of AWAKE Venture Studio. This "AI-first" model represents a new era in systematic innovation, designed to identify, prototype, and scale both internal proprietary solutions and independent AI-native startups with global reach. The launch of AWAKE is motivated by the significant efficiency gains of orders of magnitude that Making Science has already achieved through the internal integration of AI. By applying these methods, the firm has achieved a 2x acceleration in tech feature development reducing time in the deployment of AI Agents. This model has already proven its commercial and innovative power through the acceleration of startups like ad-machina, which has multiplied its value by 10 since joining the Making Science ecosystem. These proven benchmarks serve as the technical foundation for AWAKE’s two interconnected engines, which formalise this efficiency into a repeatable manufacturing process
FDA Clears First Extended Depth of Focus Contact Lens for Presbyopia23.12.2025 18:07:00 CET | Press Release
The Cataltheia Group and its U.S. subsidiary, Bruno Vision Care LLC, a leader in eye health innovation, today announced that the U.S. Food and Drug Administration (FDA) has cleared the first and only Daily Disposable Soft (Hydrophilic) Contact Lens for Presbyopia utilizing patented Extended Depth of Focus (EDOF) optical design technology, enabling commercial distribution in the United States. Deseyne® delivers smooth, continuous focus across near, intermediate, and distance vision, providing clear, natural vision without compromise. This performance is enabled by Cataltheia’s patented hyper-refractive central zone, engineered to precisely redirect light in a controlled manner. The result is a clear clinical advantage over the only other available contact lens option for presbyopia, multifocal lenses, which rely on multiple optical zones and often require prolonged visual and cognitive adaptation. “We are proud to offer the first contact lens solution for the world’s aging population th
Aramco Awards SLB Long-Term Contract to Support Kingdom’s Unconventional Gas Production Growth23.12.2025 14:58:00 CET | Press Release
Global technology company SLB (NYSE: SLB) has been awarded a five-year contract by Aramco to provide stimulation services for its unconventional gas fields. This award is part of a broader multi-billion contract, supporting one of the largest unconventional gas development programs globally. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251223074948/en/ The contract encompasses advanced stimulation, well intervention, frac automation, and digital solutions, which are important to unlocking the potential of Saudi Arabia’s unconventional gas resources. The contract encompasses advanced stimulation, well intervention, frac automation, and digital solutions, which are important to unlocking the potential of Saudi Arabia’s unconventional gas resources — a cornerstone of the Kingdom’s strategy to diversify its energy portfolio and support the global energy transition. “This agreement is an important step forward in Aramco’s effor
Tabelog, Japan's Largest (*1) Restaurant Search and Reservation Service, Launches Multilingual App for International Visitors23.12.2025 14:00:00 CET | Press Release
Tabelog (https://tabelog.com/en/), Japan's largest restaurant search and reservation service operated by Kakaku.com, Inc., launched its multilingual smartphone application (iOS/Android) for international travelers on Monday, November 17, 2025. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251221963753/en/ The Tabelog Multilingual App for International Travelers — Japan's Largest Restaurant Search and Reservation Service With approximately 100 million monthly users(*3), Tabelog is Japan's premier service widely used by Japanese locals for daily restaurant discovery. Its database is unrivaled domestically, featuring information on approximately 890,000 establishments nationwide and over 85 million reviews and photos(*4). Unlike global map services or travel sites, Tabelog is built on "authentic ratings and reviews from local Japanese users," enabling travelers to discover truly exceptional restaurants beloved by locals — not
BeOne Medicines to Present at the 44th Annual J.P. Morgan Healthcare Conference23.12.2025 12:01:00 CET | Press Release
BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced it will participate in the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026, with a presentation at 7:30 am PST. Live webcasts of these events can be accessed from the investors section of the Company’s website at https://ir.beonemedicines.com, https://hkexir.beonemedicines.com, https://sseir.beonemedicines.com. Archived replays will be available on the Company’s website. About BeOne Medicines BeOne Medicines is a global oncology company based in Switzerland that is discovering and developing innovative treatments that are more accessible to cancer patients worldwide. With a portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. With a growing global team of nearly 12,000 colleagues spanning six continents, the Company is committed to
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
